Stoke Therapeutics is focused on restoring protein expression through RNA medicine, particularly targeting genetic diseases characterized by haploinsufficiency
Stoke Therapeutics is focused on restoring protein expression through RNA medicine, particularly targeting genetic diseases characterized by haploinsufficiency. Their proprietary TANGO platform aims to increase protein output from healthy genes to treat severe diseases such as Dravet syndrome and autosomal dominant optic atrophy.